European Journal of Nutrition

, Volume 53, Issue 6, pp 1299–1311 | Cite as

Green tea catechins and blood pressure: a systematic review and meta-analysis of randomised controlled trials

  • Saman Khalesi
  • Jing SunEmail author
  • Nicholas Buys
  • Arash Jamshidi
  • Elham Nikbakht-Nasrabadi
  • Hossein Khosravi-Boroujeni



Although previous literature has reported that regular green tea consumption may improve blood pressure, the evidence from these studies is not consistent. The present study systematically reviewed randomised controlled trials and examined the effect of green tea consumption on blood pressure using meta-analysis.


Search of ProQuest, PubMed, Scopus and Cochrane Library (CENTERAL) was conducted, to identify eligible articles. Articles from 1995 to 2013 were included. A random-effect model was chosen to calculate the effect of combined trials.


Thirteen studies were included in the meta-analysis. Green tea consumption significantly changed systolic blood pressure, by −2.08 mm Hg (95 % CI −3.06, −1.05), and diastolic blood pressure, by −1.71 mm Hg (95 % CI −2.86, −0.56), compared to the control. Changes in lipid profile, blood glucose and body mass index were also assessed in the meta-analysis. A significant reduction was found in total cholesterol (−0.15 mmol/L [95 % CI −0.27, −0.02]) and low-density lipoprotein cholesterol (−0.16 mmol/L [95 % CI −0.22, −0.09]). Changes in other parameters did not reach statistical significance. Subgroup analysis suggested a greater reduction in both systolic and diastolic blood pressure in studies that included participants with a baseline mean systolic blood pressure of ≥130 mm Hg, and studies involving consuming green tea as an extract.


The present meta-analysis suggests that green tea and its catechins may improve blood pressure, and the effect may be greater in those with systolic blood pressure ≥130 mm Hg. The meta-analysis also suggests that green tea catechins may improve total and low-density lipoprotein cholesterol.


Green tea Blood Pressure Lipid profile Systematic review Meta-analysis 


Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Supplementary material

394_2014_720_MOESM1_ESM.docx (44 kb)
Supplementary material 1 (DOCX 43 kb)
394_2014_720_MOESM2_ESM.docx (30 kb)
Supplementary material 2 (DOCX 29 kb)
394_2014_720_MOESM3_ESM.docx (15 kb)
Supplementary material 3 (DOCX 14 kb)
394_2014_720_MOESM4_ESM.docx (17 kb)
Supplementary material 4 (DOCX 16 kb)


  1. 1.
    WHO (2002) World Health Organization. World Health Report 2002. Reducing risks, promoting healthy life. Geneva, Switzerland. http://wwww.hoint/whr/2002/en
  2. 2.
    WHO (2008) Global health observatory (GHO). Raised blood pressure.
  3. 3.
    Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS (2012) Heart disease and stroke statistics—2012 update a report from the American Heart Association. Circulation 125(1):e2–e220CrossRefGoogle Scholar
  4. 4.
    Law M, Wald N, Morris J (2005) Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Int J Technol Assess Health Care 21(1):145. doi: 10.1017/s0266462305220196 Google Scholar
  5. 5.
    Qureshi A, Sapkota B (2011) Blood pressure reduction in secondary stroke prevention. Continuum (Minneapolis, Minn) 17 (6 2ndary Stroke Prevention):1233Google Scholar
  6. 6.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42(6):1206–1252CrossRefGoogle Scholar
  7. 7.
    Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, Ryder JJ, Hall WL, Cassidy A (2008) Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 88(1):38–50Google Scholar
  8. 8.
    Rains TM, Agarwal S, Maki KC (2011) Antiobesity effects of green tea catechins: a mechanistic review. J Nutr Biochem 22(1):1–7CrossRefGoogle Scholar
  9. 9.
    Balentine DA, Wiseman SA, Bouwens LC (1997) The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 37(8):693–704CrossRefGoogle Scholar
  10. 10.
    Bhardwaj P, Khanna D (2013) Green tea catechins: defensive role in cardiovascular disorders. Chin J Nat Med 11(4):345–353Google Scholar
  11. 11.
    Erba D, Riso P, Bordoni A, Foti P, Biagi PL, Testolin G (2005) Effectiveness of moderate green tea consumption on antioxidative status and plasma lipid profile in humans. J Nutr Biochem 16(3):144–149. doi: 10.1016/j.jnutbio.2004.11.006 CrossRefGoogle Scholar
  12. 12.
    Maruyama K, Iso H, Sasaki S, Fukino Y (2009) The association between concentrations of green tea and blood glucose levels. J Clin Biochem Nutr 44(1):41CrossRefGoogle Scholar
  13. 13.
    Mu LN, Lu QY, Yu SZ, Jiang QW, Cao W, You NC, Setiawan VW, Zhou XF, Ding BG, Wang RH (2005) Green tea drinking and multigenetic index on the risk of stomach cancer in a Chinese population. Int J Cancer 116(6):972–983CrossRefGoogle Scholar
  14. 14.
    Sun C-L, Yuan J-M, Koh W-P, Mimi CY (2006) Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies. Carcinogenesis 27(7):1310–1315CrossRefGoogle Scholar
  15. 15.
    Antonello M, Montemurro D, Bolognesi M, Di Pascoli M, Piva A, Grego F, Sticchi D, Giuliani L, Garbisa S, Rossi GP (2007) Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts. Am J Hypertens 20(12):1321–1328CrossRefGoogle Scholar
  16. 16.
    Nagao T, Hase T, Tokimitsu I (2007) A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity 15(6):1473–1483. doi: 10.1038/oby.2007.176 CrossRefGoogle Scholar
  17. 17.
    Auvichayapat P, Prapochanung M, Tunkamnerdthai O, Sripanidkulchai B-O, Auvichayapat N, Thinkhamrop B, Kunhasura S, Wongpratoom S, Sinawat S, Hongprapas P (2008) Effectiveness of green tea on weight reduction in obese Thais: a randomized, controlled trial. Physiol Behav 93(3):486–491CrossRefGoogle Scholar
  18. 18.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269CrossRefGoogle Scholar
  19. 19.
    Liberati A, Moher D, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100. doi: 10.1371/journal.pmed.1000100 CrossRefGoogle Scholar
  20. 20.
    Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Commun Health 52(6):377–384CrossRefGoogle Scholar
  21. 21.
    Cohen J (1992) A power primer. Psychol Bull 112(1):155–159. doi: 10.1037/0033-2909.112.1.155 CrossRefGoogle Scholar
  22. 22.
    Harrison RA, Siminoski K, Vethanayagam D, Majumdar SR (2007) Osteoporosis-related kyphosis and impairments in pulmonary function: a systematic review. J Bone Miner Res 22(3):447–457CrossRefGoogle Scholar
  23. 23.
    Higgins J, Green SP, Wiley I, Cochrane C (2008) Cochrane handbook for systematic reviews of interventions. vol Book, Whole. Wiley-Blackwell, HobokenCrossRefGoogle Scholar
  24. 24.
    Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, Medical Research Council, UKGoogle Scholar
  25. 25.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188. doi: 10.1016/0197-2456(86)90046-2 CrossRefGoogle Scholar
  26. 26.
    Kim A, Chiu A, Barone MK, Avino D, Wang F, Coleman CI, Phung OJ (2011) Green tea catechins decrease total and low-density lipoprotein cholesterol: a systematic review and meta-analysis. J Am Diet Assoc 111(11):1720–1729CrossRefGoogle Scholar
  27. 27.
    Dong J-Y, Szeto IM, Makinen K, Gao Q, Wang J, Qin L-Q, Zhao Y (2013) Effect of probiotic fermented milk on blood pressure: a meta-analysis of randomised controlled trials. Br J Nutr 110(07):1188–1194CrossRefGoogle Scholar
  28. 28.
    Sone T, Kuriyama S, Nakaya N, Hozawa A, Shimazu T, Nomura K, Rikimaru S, Tsuji I (2011) Randomized controlled trial for an effect of catechin-enriched green tea consumption on adiponectin and cardiovascular disease risk factors. Food Nutr Res 55:1–10. doi: 10.3402/fnr.v55i0.8326 CrossRefGoogle Scholar
  29. 29.
    Basu A, Du M, Sanchez K, Leyva MJ, Betts NM, Blevins S, Wu M, Aston CE, Lyons TJ (2011) Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome. Nutrition 27(2):206–213. doi: 10.1016/j.nut.2010.01.015 CrossRefGoogle Scholar
  30. 30.
    Fukino Y, Shimbo M, Aoki N, Okubo T, Iso H (2005) Randomized controlled trial for an effect of green tea consumption on insulin resistance and inflammation markers. J Nutr Sci Vitaminol (Tokyo) 51(5):335–342CrossRefGoogle Scholar
  31. 31.
    Bogdanski P, Suliburska J, Szulinska M, Stepien M, Pupek-Musialik D, Jablecka A (2012) Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients. Nutr Res 32(6):421–427. doi: 10.1016/j.nutres.2012.05.007 CrossRefGoogle Scholar
  32. 32.
    Frank J, George TW, Lodge JK, Rodriguez-Mateos AM, Spencer JP, Minihane AM, Rimbach G (2009) Daily consumption of an aqueous green tea extract supplement does not impair liver function or alter cardiovascular disease risk biomarkers in healthy men. J Nutr 139(1):58–62. doi: 10.3945/jn.108.096412 CrossRefGoogle Scholar
  33. 33.
    Hsu CH, Liao YL, Lin SC, Tsai TH, Huang CJ, Chou P (2011) Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebo-controlled clinical trial. Altern Med Rev 16(2):157–163CrossRefGoogle Scholar
  34. 34.
    Hsu CH, Tsai TH, Kao YH, Hwang KC, Tseng TY, Chou P (2008) Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr 27(3):363–370CrossRefGoogle Scholar
  35. 35.
    Nagao T, Hase T, Tokimitsu I (2007) A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity (Silver Spring) 15(6):1473–1483. doi: 10.1038/oby.2007.176 CrossRefGoogle Scholar
  36. 36.
    Nantz MP, Rowe CA, Bukowski JF, Percival SS (2009) Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. Nutrition 25(2):147–154CrossRefGoogle Scholar
  37. 37.
    Suliburska J, Bogdanski P, Szulinska M, Stepien M, Pupek-Musialik D, Jablecka A (2012) Effects of green tea supplementation on elements, total antioxidants, lipids, and glucose values in the serum of obese patients. Biol Trace Elem Res 149(3):315–322. doi: 10.1007/s12011-012-9448-z CrossRefGoogle Scholar
  38. 38.
    Vieira Senger AE, Schwanke CHA, Gomes I, Valle Gottlieb MG (2012) Effect of green tea (Camellia sinensis) consumption on the components of metabolic syndrome in elderly. J Nutr Health Aging 16(9):738–742. doi: 10.1007/s12603-012-0081-5 CrossRefGoogle Scholar
  39. 39.
    Diepvens K, Kovacs EM, Nijs IM, Vogels N, Westerterp-Plantenga MS (2005) Effect of green tea on resting energy expenditure and substrate oxidation during weight loss in overweight females. Br J Nutr 94(6):1026–1034CrossRefGoogle Scholar
  40. 40.
    Chantre P, Lairon D (2002) Recent findings of green tea extract AR25 (exolise) and its activity for the treatment of obesity. Phytomedicine 9(1):3–8CrossRefGoogle Scholar
  41. 41.
    Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH (1995) Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 155(7):701–709. doi: 10.1001/archinte.1995.00430070053006 CrossRefGoogle Scholar
  42. 42.
    Islam MA (2012) Cardiovascular effects of green tea catechins: progress and promise. Recent Pat Cardiovasc Drug Discov 7(2):88–99CrossRefGoogle Scholar
  43. 43.
    Rastaldo R, Pagliaro P, Cappello S, Penna C, Mancardi D, Westerhof N, Losano G (2007) Nitric oxide and cardiac function. Life Sci 81(10):779–793CrossRefGoogle Scholar
  44. 44.
    Gössl M, Lerman A (2006) Endothelin beyond a vasoconstrictor. Circulation 113(9):1156–1158CrossRefGoogle Scholar
  45. 45.
    Collins QF, Liu H-Y, Pi J, Liu Z, Quon MJ, Cao W (2007) Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5′-AMP-activated protein kinase. J Biol Chem 282(41):30143–30149CrossRefGoogle Scholar
  46. 46.
    Pon Anandh B, Dongmin L (2008) Green tea catechins and cardiovascular health: an update. Curr Med Chem 15(18):1840–1850. doi: 10.2174/092986708785132979 CrossRefGoogle Scholar
  47. 47.
    Maron DJ, Lu GP, Cai NS, Wu ZG, Li YH, Chen H, Zhu JQ, Jin XJ, Wouters BC, Zhao J (2003) Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. Arch Intern Med 163(12):1448–1453CrossRefGoogle Scholar
  48. 48.
    Koo SI, Noh SK (2007) Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect. J Nutr Biochem 18(3):179–183CrossRefGoogle Scholar
  49. 49.
    Bursill CA, Abbey M, Roach PD (2007) A green tea extract lowers plasma cholesterol by inhibiting cholesterol synthesis and upregulating the LDL receptor in the cholesterol-fed rabbit. Atherosclerosis 193(1):86–93CrossRefGoogle Scholar
  50. 50.
    Ikeda I, Kobayashi M, Hamada T, Tsuda K, Goto H, Imaizumi K, Nozawa A, Sugimoto A, Kakuda T (2003) Heat-epimerized tea catechins rich in gallocatechin gallate and catechin gallate are more effective to inhibit cholesterol absorption than tea catechins rich in epigallocatechin gallate and epicatechin gallate. J Agric Food Chem 51(25):7303–7307CrossRefGoogle Scholar
  51. 51.
    Hsu T, Kusumoto A, Abe K, Hosoda K, Kiso Y, Wang M, Yamamoto S (2006) Polyphenol-enriched oolong tea increases fecal lipid excretion. Eur J Clin Nutr 60(11):1330–1336CrossRefGoogle Scholar
  52. 52.
    Westerterp-Plantenga MS (2010) Green tea catechins, caffeine and body-weight regulation. Physiol Behav 100(1):42–46CrossRefGoogle Scholar
  53. 53.
    Rains TM, Agarwal S, Maki KC (2011) Antiobesity effects of green tea catechins: a mechanistic review. J Nutr Biochem 22(1):1–7CrossRefGoogle Scholar
  54. 54.
    Henning SM, Fajardo-Lira C, Lee HW, Youssefian AA, Go VL, Heber D (2003) Catechin content of 18 teas and a green tea extract supplement correlates with the antioxidant capacity. Nutr Cancer 45(2):226–235CrossRefGoogle Scholar
  55. 55.
    Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM (2005) Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J Hypertens 23(5):921–928CrossRefGoogle Scholar
  56. 56.
    Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJP, Bittner V, Fruchart J-C, Treating New Targets I, Treating to New Targets I (2007) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357(13):1301–1310. doi: 10.1056/NEJMoa064278 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Saman Khalesi
    • 1
  • Jing Sun
    • 1
    • 2
    Email author
  • Nicholas Buys
    • 1
  • Arash Jamshidi
    • 3
    • 4
  • Elham Nikbakht-Nasrabadi
    • 1
  • Hossein Khosravi-Boroujeni
    • 1
  1. 1.Griffith Health InstituteGriffith UniversityGold CoastAustralia
  2. 2.School of MedicineGriffith UniversityGold CoastAustralia
  3. 3.Nephrology and UrologySina General HospitalTehranIran
  4. 4.Supplementary Medicine DepartmentSondos Teb CoTehranIran

Personalised recommendations